Certain supplemental information not included in the press release

EX-99.2 3 dex992.htm CERTAIN SUPPLEMENTAL INFORMATION NOT INCLUDED IN THE PRESS RELEASE Certain supplemental information not included in the press release

Exhibit 99.2

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

FIRST QUARTER

2008

EQUITY INCOME FROM AFFILIATES (millions of dollars)


	1Q `08		1Q `07
MERCK / SCHERING-PLOUGH	$	392.8	$	347.2
ASTRAZENECA LP		131.1		211.9
Other⁽¹⁾		128.2		93.5

TOTAL	$	652.1	$	652.6

⁽¹⁾	Primarily reflects results for Merial Limited, Sanofi Pasteur-MSD and Johnson & JohnsonºMerck Consumer Pharmaceuticals.

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a “NET” basis.


Merial	1Q `08		1Q `07
FRONTLINE, other fipronil	$	341.6	$	327.6
BIOLOGICALS		174.4		153.3
IVOMEC, HEARTGARD, other avermectins		146.1		137.4
Other Animal Health		71.5		59.4

TOTAL MERIAL SALES	$	733.6	$	677.7


Sanofi Pasteur-MSD	1Q `08		1Q `07
GARDASIL	$	239.8	$	30.2
VIRAL VACCINES		22.7		20.1
HEPATITIS VACCINES		18.0		16.7
Other Vaccines		130.9		127.8

TOTAL SANOFI PASTEUR-MSD SALES	$	411.4	$	194.8


Merck / Schering-Plough Collaboration	1Q `08		1Q `07
VYTORIN	$	651.2	$	623.8
ZETIA		581.7		544.0

TOTAL MERCK / SCHERING-PLOUGH SALES	$	1,232.9	$	1,167.8

OTHER (INCOME) EXPENSE, NET (millions of dollars)


	1Q `08		1Q `07
INTEREST INCOME	$	(169.5)	$	(181.7)
INTEREST EXPENSE		72.6		102.4
EXCHANGE LOSSES (GAINS)		12.6		(19.6)
MINORITY INTERESTS		31.9		30.6
Other, net ⁽¹⁾		(2,124.9)		(187.7)

TOTAL	$	(2,177.3)	$	(256.0)

⁽¹⁾	Other, net in the first quarter of 2008 primarily reflects a gain of $2.2 billion related to a distribution from AstraZeneca LP.

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

FIRST QUARTER

2008

NET PRODUCT SALES DETAIL (millions of dollars)


	1Q `08 vs. 1Q `07
PRODUCT	TOTAL % CHG		TOTAL $	U.S. % CHG		U.S. $	Foreign % CHG		Foreign $
COZAAR / HYZAAR	6	%	847	-2	%	299	11	%	548
FOSAMAX	-37	%	470	-58	%	202	3	%	268
SINGULAIR	10	%	1,104	1	%	714	33	%	389
Vaccines:
GARDASIL	7	%	390	-6	%	293	82	%	97
ROTATEQ	*		190	*		179	*		11
ZOSTAVAX	72	%	74	72	%	73	N/A		—
OTHER VIRAL VACCINES ⁽¹⁾	-8	%	226	-11	%	202	25	%	24
HEPATITIS VACCINES	-53	%	34	-59	%	25	-21	%	9
OTHER VACCINES	-21	%	73	-55	%	29	65	%	43
Other Reported Products:
ARCOXIA	16	%	93	N/A		—	16	%	93
CANCIDAS	11	%	149	-22	%	30	24	%	119
COSOPT / TRUSOPT	8	%	201	-3	%	81	17	%	121
CRIXIVAN / STOCRIN	-9	%	75	-36	%	4	-6	%	72
EMEND	25	%	60	12	%	40	66	%	19
INVANZ	33	%	55	25	%	28	43	%	27
ISENTRESS	*		47	*		30	*		17
JANUVIA	*		272	*		228	*		44
JANUMET	*		58	*		55	*		4
MAXALT	13	%	122	11	%	79	17	%	43
PRIMAXIN	3	%	203	-16	%	51	11	%	152
PROPECIA	10	%	105	1	%	37	16	%	68
PROSCAR	-32	%	85	-88	%	3	-17	%	82
TIMOPTIC / TIMOPTIC XE	1	%	29	-13	%	2	2	%	27
VASOTEC / VASERETIC	-21	%	96	N/A		—	-21	%	96
ZOCOR	-31	%	179	-60	%	28	-20	%	151
ZOLINZA	72	%	4	61	%	4	N/A		—

*	100% or over

N/A - Not Applicable

⁽¹⁾	- Includes ProQuad, M-M-R II and Varivax.

TOTAL SALES: VOLUME, PRICE, EXCHANGE


	1Q ‘08		% CHG		VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	$	5,822	1	%	-2	-2	4

U.S. ($ MM)		3,296	-6	%	-6	—	N/A
Foreign ($ MM)		2,526	12	%	5	-4	11